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Since we have no choice butto be swept along by[this]vasttechnological surge, we might as well learn to surf.
Michael Soule
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Rethinking
Thalidomide
New research indicates
that the controversial
drug thalidomide, which
caused severe birth defor-
mities when taken as a
sedative and hypnotic by
pregnant women in the
1960s, may be useful in
treating diseases that
cause blindness.
Robert D'Amato, a
researcher at the Child-
ren's Hospital at Harvard
Medical School, came
across thalidomide while
searching for drugs to
treat two diseases that
cause blindness, macular
degeneration and diabetic
retinopathy. Both dis-
eases cause excess growth of blood vessels
which burst in the eye and destroyvision.
D'Amato, an ophthalmologist with a
Ph.D. in neuroscience, said that in looking
for a drug that stops blood vessel growth,
or an angiogenesis inhibitor, he realized
such a drug would have left a trail ofclues.
It occurred to him that an angiogenesis
inhibitor would cause menstrual periods to
stop, as well as cause birth defects. He con-
ducted a medical literature search for drugs
that caused these side effects, and hit upon
thalidomide. "Thalidomide was one drug
that fit the profile, because it had the
appropriate side effects for an angiogenesis
inhibitor," he said.
D'Amato theorized that the reason
thalidomide causes birth defects is that it
acts during angiogenesis to affect blood
vessels offetuses. He said that for 30 years,
scientists had been trying to figure out
how thalidomide affects fetuses, but no
one had studied blood vessels. It has only
been in the last 10 years that scientists have
been able to grow blood vessels in cultures
to study them. D'Amato set out to prove
that thalidomide is indeed an angiogenesis
inhibitor, and as such may present a possi-
ble treatment for macular degeneration
and diabetic retinopathy.
Diabetic retinopathy results from high
blood sugar levels that lead to a scarcity of
blood in the retina. To compensate, the
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Eyes on thalidomide. New research suggests the drug may be used to treat diseases such as
maculardegeneration.
retina produces factors that encourage
blood vessels to grow into a tangled mass,
interfering with vision. The disease can be
treated with lasers, which burn away the
excess vessels, but only if the vessels
haven't reached the retina.
Macular degeneration, which mostly
affects people over the age of 65, results
from a blood vessel growing under the
macula, the center ofthe retina, that blocks
vision. Some cases can be alleviated by
treating the blood vessel from the side with
a laser, but the process still affects vision.
D'Amato teamed up with Michael
Loughnan, an Australian ophthalmologist,
to test thalidomide on rabbits. They surgi-
cally implanted a substance that encour-
ages blood-vessel growth in a pocket ofthe
rabbits' corneas, causing a stream ofvessels
to grow across the cornea. The researchers
then administered thalidomide and various
compounds ofthalidomide orally, to see if
any of the drugs could halt the blood-ves-
sel growth. The only successful com-
pounds were the ones that inhibited blood
vessel growth and caused birth defects,
thus supporting D'Amato's theory.
D'Amato said that thalidomide alone
worked the best to halt blood vessel
growth. The eyes of the rabbits that were
given thalidomide had only a scattering of
blood vessels around the growth pocket.
Since this discovery in December
1992, the researchers
have conducted tests on
mice and found similar
results. The FDA grant-
ed D'Amato approval for
clinical trials to begin in
January 1995. The re-
searchers will test men
and postmenopausal
women with macular
degeneration. D'Amato
said results will not be
seen for at least a year. If
the tests prove successful,
however, a widespread
treatment for macular
degeneration would most
likely be available around
January 1996.
And, if the tests go
well, the researchers
would then begin testing
thalidomide for treatment of diabetic
retinopathy. However, D'Amato said they
would first test diabetic men only. If suc-
cess is seen in the male diabetics, they will
begin testing women. D'Amato said, "If
we were going to use thalidomide in pre-
menopausal women, we would have to be
assured that they wouldn't get pregnant."
D'Amato said the reaction to the new
therapy has been tremendous. "The idea of
taking a pill to relieve this is novel," he
said.
Fighting for Air
Air pollution must be turned into the pub-
lic nemesis that cigarette smoking has
become. This underlying tenet from a con-
ference sponsored by the National Assoc-
iation of Physicians for the Environment
(NAPE) on November 18 will be devel-
oped into a major public education cam-
paign targeting both the scientific commu-
nity and the public.
In fact, much ofthe material for NAPE's
anti-air pollution campaign will be drawn
from the November conference detailing the
impact ofair pollution on body organs and
systems. During that conference, scientific
experts warned that lack ofovert symptoms
does not mean lack ofadverse effects, and
that the ravages ofair pollution are not lim-
ited to the respiratory tract. "It's not just the
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